BridgeBio Pharma, Inc. (BBIO)
63.93
-4.38
(-6.41%)
USD |
NASDAQ |
Feb 25, 13:57
BridgeBio Pharma Research and Development Expense (Quarterly) : 112.87M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Insmed, Inc. | 254.91M |
| Mirum Pharmaceuticals, Inc. | 42.90M |
| Cogent Biosciences, Inc. | 74.38M |
| Alnylam Pharmaceuticals, Inc. | 372.22M |
| Sarepta Therapeutics, Inc. | 218.89M |